Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 28, Issue 32, Pages 4790-4799Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2010.28.3473
Keywords
-
Categories
Funding
- Public Health Service, National Institute of Health [CA23099, CA21765]
- American Lebanese Syrian Associated Charities
- Research Councils United Kingdom
- Cancer Research United Kingdom
- Engineering and Physical Sciences Research Council [EP/C509005/1] Funding Source: researchfish
Ask authors/readers for more resources
Numerous studies have documented that adolescents and young adults (AYAs) experience a significant cancer burden as well as significant cancer mortality compared with other age groups. The reasons for the disparate outcomes of AYAs and other age groups are not completely understood and are likely to be multifactorial, including a range of sociodemographic issues unique to these individuals as well as differences between adolescents, younger pediatric patients, and adults in the pharmacology of anticancer agents. Because adolescence is a period of transition from childhood to early adulthood, numerous physical, physiologic, cognitive, and behavioral changes occur during this time. In this review, we provide an overview of the unique developmental physiology of the adolescent and explain how these factors and the behavioral characteristics of adolescents may affect the pharmacology of anticancer agents in this patient population. Finally, we describe examples of studies that have assessed the relation between drug disposition and age, focusing on the AYA age group.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available